A pharmaceutical composition suitable for use in a dry powder inhaler comprising 70 mass %-99.5 mass % of pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulation and 0.1 mass %-12.5 mass % of salmeterol xinafoate and 0.4 mass %-17.5 mass % of fluticasone propionate.